Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1880 1
1888 3
1953 1
1958 1
1964 1
1968 1
1972 1
1974 1
1975 1
1976 1
1977 1
1978 1
1979 1
1980 2
1982 1
1983 2
1985 2
1986 8
1987 6
1988 9
1989 18
1990 5
1991 6
1992 14
1993 6
1994 10
1995 8
1996 8
1997 7
1998 9
1999 8
2000 8
2001 4
2002 11
2003 12
2004 14
2005 19
2006 17
2007 19
2008 25
2009 19
2010 21
2011 24
2012 16
2013 33
2014 44
2015 24
2016 37
2017 32
2018 40
2019 22
2020 47
2021 47
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

634 results
Results by year
Filters applied: . Clear all
Page 1
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. Among authors: pollock c. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
Mechanisms of cancer metastasis to the bone.
Yin JJ, Pollock CB, Kelly K. Yin JJ, et al. Among authors: pollock cb. Cell Res. 2005 Jan;15(1):57-62. doi: 10.1038/sj.cr.7290266. Cell Res. 2005. PMID: 15686629 Review.
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Sarraju A, et al. Among authors: pollock c. Am Heart J. 2021 Mar;233:141-148. doi: 10.1016/j.ahj.2020.12.008. Epub 2020 Dec 22. Am Heart J. 2021. PMID: 33358942 Clinical Trial.
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V; CREDENCE Study Investigators. Jardine MJ, et al. Among authors: pollock c. J Am Soc Nephrol. 2020 May;31(5):1128-1139. doi: 10.1681/ASN.2019111168. J Am Soc Nephrol. 2020. PMID: 32354987 Free PMC article. Clinical Trial.
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V. Bakris G, et al. Among authors: pollock c. Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1705-1714. doi: 10.2215/CJN.10140620. Epub 2020 Nov 19. Clin J Am Soc Nephrol. 2020. PMID: 33214158 Free PMC article. Clinical Trial.
Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
Khoo CM, Deerochanawong C, Chan SP, Matawaran B, Sheu WH, Chan J, Mithal A, Luk A, Suastika K, Yoon KH, Ji L, Man NH, Pollock C. Khoo CM, et al. Among authors: pollock c. Diabetes Obes Metab. 2021 Feb;23(2):299-317. doi: 10.1111/dom.14251. Epub 2020 Nov 20. Diabetes Obes Metab. 2021. PMID: 33155749 Free PMC article. Review.
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Cannon CP, et al. Among authors: pollock c. Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11. Circulation. 2020. PMID: 31707795 Clinical Trial. No abstract available.
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V. Mahaffey KW, et al. Among authors: pollock c. Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11. Circulation. 2019. PMID: 31291786 Free PMC article. Clinical Trial.
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Neuen BL, Arnott C, Perkovic V, Figtree G, de Zeeuw D, Fulcher G, Jun M, Jardine MJ, Zoungas S, Pollock C, Mahaffey KW, Neal B, Heerspink HJL. Neuen BL, et al. Among authors: pollock c. Diabetes Obes Metab. 2021 Feb;23(2):382-390. doi: 10.1111/dom.14226. Epub 2020 Oct 29. Diabetes Obes Metab. 2021. PMID: 33043620 Free PMC article.
Mouse Models of Diabetes, Obesity and Related Kidney Disease.
Glastras SJ, Chen H, Teh R, McGrath RT, Chen J, Pollock CA, Wong MG, Saad S. Glastras SJ, et al. Among authors: pollock ca. PLoS One. 2016 Aug 31;11(8):e0162131. doi: 10.1371/journal.pone.0162131. eCollection 2016. PLoS One. 2016. PMID: 27579698 Free PMC article.
634 results